SOPHiA GENETICS to Highlight Innovations and Announcements at Investor Day on September 20, 2022
September 20 2022 - 6:43AM
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in
the healthcare space, will host its first-ever Investor Day TODAY
in-person at PUBLIC Hotel in New York City. The event will begin at
1:30 p.m. EDT and is expected to conclude at approximately 5:30
p.m. EDT.
Presenters include:
- Troy Cox, Chairman of the board
- Dr. Jurgi Camblong, Chief Executive Officer and co-founder
- Ken Freedman, Chief Revenue Officer
- Peter Casasanto, Chief BioPharma Officer
- Dr. Philippe Menu, Chief Medical Officer
- Abhi Verma, Chief Technology Officer
- Dr. Zhenyu Xu, Chief Scientific Officer
- Ross Muken, Chief Financial Officer
Today’s Investor Day will offer an opportunity for investors to
learn from the company’s executive team about its key
differentiators and strategies that will help drive SOPHiA
Genetics’ long-term growth.
Due to limited capacity, advanced registration is required for
in-person attendance. For more information, interested parties may
contact Investor Relations at ir@sophiagenetics.com.
Additionally, the event will be webcast live and all interested
parties are invited to access the webcast from the Investor
Relations section of the company’s website.
About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq:
SOPH) is a software company dedicated to establishing the practice
of data-driven medicine as the standard of care and for life
sciences research. It is the creator of the SOPHiA DDM™ Platform, a
cloud-native platform capable of analyzing data and generating
insights from complex multimodal data sets and different diagnostic
modalities. The SOPHiA DDM™ Platform and related solutions,
products and services are currently used by a broad network of
hospital, laboratory, and biopharma institutions globally. For more
information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn, Facebook, and Instagram. Where others see data, we see
answers
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements: This press release
contains statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management’s beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Investor Contact:Jennifer PottageHead of
Investor Relationsir@sophiagenetics.com
Media Contact:Kelly KatapodisSenior Manager,
Media & Communicationsmedia@sophiagenetics.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jul 2023 to Jul 2024